The future of clinical toxicology lies in personalized medicine and the integration of genomics and proteomics into toxicological assessments. Understanding individual genetic susceptibilities to toxins will enable more precise risk assessments and tailored treatment strategies. Furthermore, the development of real-time monitoring tools and biosensors holds promise for rapid detection and response to toxic exposures.
